ANGIO-EX study: to determine whether the blood circulating protein angiopoietin like-2 (angptl2) is associated with a poor vessel health in young and old healthy volunteers, patients with a coronary artery heart disease and in obese subjects

A randomized trial to determine whether circulating levels of angptl2 correlates with the improvement in cardiopulmonary fitness associated with a exercise training-based secondary prevention in coronary artery disease patients and obese subjects compared to age-matched healthy, physically active volunteers

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN46169845

Enrollment

Registered

2013-02-27

Start date

2012-01-15

Completion date

Unknown

Last updated

2017-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aging and age-related cardiovascular diseases Circulatory System Cardiovascular disease, unspecified

Interventions

Phase 1 will consist of measuring angptl2 in the blood extracted from two groups of healthy and physically trained volunteers (men and women) and a group of obese subject (men and women). At enrolment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: In phase 1, two groups (n=20 each) of healthy and physically trained volunteer members (men and women) of aged 18 to 39 years and 50 to 70 years. Obese subjects (n=20) aged 50 to 70 years, men and women. Healthy subjects are defined as men and women without cardiac, pulmonary or muscular diseases. Obese patients are recruited at a BMI >30 kg/m2, without cardiac, pulmonary and muscular disease. In phase 2 of the study, newly referred patients with CHD (n=20) aged 50 to 70 years, and obese subjects (n=20) aged 50 to 70 years, men and women. Inclusion criteria for CHD patients are: 1. Documented prior acute coronary syndrome 2. Documented coronary revascularization or documented myocardial ischemia or necrosis on myocardial scintigraphy. Obese patients are recruited at a BMI >30 kg/m2, without cardiac, pulmonary and muscular disease.

Exclusion criteria

Exclusion criteria: Active smokers (=1 cigarette per day) are excluded. Exclusion criteria for healthy subjects: 1. Dyslipidemia (total cholesterol > 5.20 mM 2. HDL 2.60 mM 4. Triglycerides > 1.7 mM or use of lipid-lowering therapy) 5. Hypertension (SBP >140 or DBP >90 mmHg or use of antihypertensive medications) 6. Treated or untreated diabetes mellitus 7. Impaired fasting glucose (>5.6 mM) 8. Overweight or obesity (BMI>25 kg/m2) 9. Abdominal obesity (waist circumference >90 cm in men, 80 cm in women) 10. Documented CHD (prior acute coronary syndrome, prior coronary revascularization, presence of myocardial ischemia or necrosis on myocardial scintigraphy), and for any other contraindication to exercise testing/training. Exclusion criteria for CHD patients are: 1. Recent acute coronary event (within one month of inclusion) 2. History of exercise-induced or severe arrhythmias, unstable angina, pacemaker or defibrillator, presence of a pulmonary or skeletal muscle disease limiting maximal exercise testing/training 3. Body mass index (BMI) >28 kg/m2. Exclusion criteria for obese subjects is the presence of a pulmonary or skeletal muscle disease limiting maximal exercise testing/training.

Design outcomes

Primary

Measure	Time frame
Measure of circulating levels of angptl2	—

Secondary

Measure	Time frame
To demonstrate modifications in biomarkers including leukocyte epigenetic changes after a secondary prevention program	—

Countries

Canada

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026